JP7057668B2 - 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 - Google Patents
治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 Download PDFInfo
- Publication number
- JP7057668B2 JP7057668B2 JP2017513004A JP2017513004A JP7057668B2 JP 7057668 B2 JP7057668 B2 JP 7057668B2 JP 2017513004 A JP2017513004 A JP 2017513004A JP 2017513004 A JP2017513004 A JP 2017513004A JP 7057668 B2 JP7057668 B2 JP 7057668B2
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- ercc1 isoform
- ercc1
- protein
- isoform
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000001708 Protein Isoforms Human genes 0.000 title claims description 129
- 108010029485 Protein Isoforms Proteins 0.000 title claims description 129
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 title claims description 128
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 title claims description 128
- 108020004999 messenger RNA Proteins 0.000 title claims description 84
- 108090000623 proteins and genes Proteins 0.000 title claims description 51
- 102000004169 proteins and genes Human genes 0.000 title claims description 50
- 229940124597 therapeutic agent Drugs 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 45
- 239000003814 drug Substances 0.000 title claims description 34
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 44
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 21
- 239000012830 cancer therapeutic Substances 0.000 claims description 18
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 16
- 229910052697 platinum Inorganic materials 0.000 claims description 16
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 239000000090 biomarker Substances 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 230000005291 magnetic effect Effects 0.000 claims description 5
- 206010003445 Ascites Diseases 0.000 claims description 4
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 4
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 230000005298 paramagnetic effect Effects 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 238000003757 reverse transcription PCR Methods 0.000 claims description 4
- 241000342334 Human metapneumovirus Species 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 2
- 239000006249 magnetic particle Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 239000000523 sample Substances 0.000 description 22
- 238000003745 diagnosis Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000001514 detection method Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 5
- 102100023123 Mucin-16 Human genes 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000011518 platinum-based chemotherapy Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000007298 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185247.5 | 2014-09-18 | ||
| EP14185247 | 2014-09-18 | ||
| PCT/EP2015/071170 WO2016042009A1 (en) | 2014-09-18 | 2015-09-16 | Mrna and/or protein of ercc1 isoform 3 for use in diagnosing a resistance against a therapeutic agent and method for diagnosing a resistance against a therapeutic agent using said mrna and/or protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168483A Division JP2021019612A (ja) | 2014-09-18 | 2020-10-05 | 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529074A JP2017529074A (ja) | 2017-10-05 |
| JP2017529074A5 JP2017529074A5 (enExample) | 2018-08-23 |
| JP7057668B2 true JP7057668B2 (ja) | 2022-04-20 |
Family
ID=51542262
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513004A Active JP7057668B2 (ja) | 2014-09-18 | 2015-09-16 | 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 |
| JP2020168483A Pending JP2021019612A (ja) | 2014-09-18 | 2020-10-05 | 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168483A Pending JP2021019612A (ja) | 2014-09-18 | 2020-10-05 | 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170233826A1 (enExample) |
| EP (1) | EP3194616B1 (enExample) |
| JP (2) | JP7057668B2 (enExample) |
| WO (1) | WO2016042009A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200377955A1 (en) * | 2017-06-20 | 2020-12-03 | Liquid Genomics, Inc. | USE OF CELL-FREE CIRCULATING RNA (cfRNA) EXPRESSION OF PD-L1 AND ERCC1 IN PLASMA TO MONITOR RESPONSE TO THERAPY IN NSCLC |
| WO2022098086A1 (ko) * | 2020-11-04 | 2022-05-12 | 한국과학기술원 | 비기능성 전사체를 이용한 parp 저해제 또는 dna 손상 약물 감수성 판정방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003023057A2 (de) * | 2001-09-06 | 2003-03-20 | Adnagen Ag | Verfahren und diagnose-kit zur selektionierung und/oder zum qualitativen und/oder quantitativen nachweis von zellen |
| US9702875B2 (en) * | 2006-03-14 | 2017-07-11 | Institute Gustave-Roussy | Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy |
| CA2647843A1 (en) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection of proteins from circulating neoplastic cells |
| EP2233589A1 (en) * | 2009-03-19 | 2010-09-29 | Institut Gustave Roussy | MSH2 and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer |
| EP2473619A4 (en) * | 2009-09-03 | 2013-03-27 | Scripps Research Inst | METHOD FOR CATEGORIZING CIRCULATING TUMOR CELLS |
| EP2628008B1 (en) * | 2010-10-14 | 2017-05-31 | Janssen Diagnostics, LLC | Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents |
-
2015
- 2015-09-16 JP JP2017513004A patent/JP7057668B2/ja active Active
- 2015-09-16 WO PCT/EP2015/071170 patent/WO2016042009A1/en not_active Ceased
- 2015-09-16 EP EP15766784.1A patent/EP3194616B1/en active Active
- 2015-09-16 US US15/511,837 patent/US20170233826A1/en not_active Abandoned
-
2020
- 2020-10-05 JP JP2020168483A patent/JP2021019612A/ja active Pending
Non-Patent Citations (2)
| Title |
|---|
| Ｃｌｉｎｉｃａｌ Ｃｈｅｍｉｓｔｒｙ，２０１４年，Ｖｏｌ．６０，Ｎｏ．１０，ｐ．１２８２－１２８９ |
| Ｔｈｅ Ｎｅｗ Ｅｎｇｌａｎｄ Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎｅ，２０１３年，Ｖｏｌ．３６８，Ｎｏ．１２，ｐ．１１０１－１１１０ |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021019612A (ja) | 2021-02-18 |
| WO2016042009A1 (en) | 2016-03-24 |
| US20170233826A1 (en) | 2017-08-17 |
| EP3194616A1 (en) | 2017-07-26 |
| JP2017529074A (ja) | 2017-10-05 |
| EP3194616B1 (en) | 2020-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hudler et al. | Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics | |
| de Albuquerque et al. | Multimarker analysis of circulating tumor cells in peripheral blood of metastatic breast cancer patients: a step forward in personalized medicine | |
| Li et al. | Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead‐Assisted Flow Cytometry Detection of Tumor‐Derived Extracellular Vesicles | |
| CN106233143B (zh) | 癌症治疗 | |
| Stephan et al. | Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. | |
| Chen et al. | Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer | |
| EP2449383B1 (en) | Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms | |
| Wang et al. | Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy | |
| JP2021019612A (ja) | 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 | |
| JP6192122B2 (ja) | 結腸直腸癌診断および予測のためのバイオマーカー | |
| Aufderklamm et al. | XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence | |
| JP5568807B2 (ja) | プロテオミクス解析を用いたメラノーママーカーの同定 | |
| Musrap et al. | Proteomic analysis of cancer and mesothelial cells reveals an increase in Mucin 5AC during ovarian cancer and peritoneal interaction | |
| US20200232039A1 (en) | Adm2 gene marker for diagnosis or prognosis prediction of thyroid cancer and uses thereof | |
| KR101297309B1 (ko) | 폐암 진단용 조성물 및 폐암 진단키트 | |
| US11840734B2 (en) | Method for analyzing aurka expression | |
| JP7453284B2 (ja) | 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ | |
| EP2574929A1 (en) | Marker in diagnosing prostate cancer (PC) | |
| JP2016514248A5 (enExample) | ||
| CN104531878B (zh) | 一种联合lncRNA和AR3检测试剂盒及应用 | |
| US20090233295A1 (en) | Trim59 directed diagnostics for neoplastic disease | |
| EP2320235A1 (en) | Marker for prostate cancer diagnosis | |
| JP2017529074A5 (enExample) | ||
| JP2010216826A (ja) | 新規腫瘍マーカーを用いた乳癌の検査方法 | |
| Ak et al. | Nectin-2 and nectin-4 adhesion molecules in patients with breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180711 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180711 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190605 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190904 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191205 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201005 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201005 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201029 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201030 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20201211 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20201215 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210702 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20210903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211130 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220302 |
|
| C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20220311 |
|
| C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20220407 |
|
| C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20220407 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220408 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7057668 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |